Pharmaceutical News

RSS

Researchers discover small molecules that kill HPV-infected cancer cells

Researchers at The Wistar Institute announce the discovery of small molecules that kill cancer cells caused by infection with human papillomavirus (HPV). Their results, in both cell and mouse models, demonstrate that the small molecule inhibitors protect a tumor-suppressing protein targeted by viral proteins, thus killing the infected tumor cells.

27 Apr 2012

Blog posts report on International Treatment as Prevention conference in Vancouver

Two separate posts in the Center for Global Health Policy's "Science Speaks" blog report on the International Treatment as Prevention conference in Vancouver. The first post recaps an update from Stephen Becker of the Bill & Melinda Gates Foundation on Tuesday "about the Foundation's treatment optimization activities," writing, "According to Becker, the Foundation acknowledges that treatment will be at the center of HIV prevention efforts, but 'no amount of treatment will obviate the need for primary prevention modalities.'"

27 Apr 2012

Combination of Velcade and Fasudil could treat NSCLC

A common cancer drug and a drug used for a rare condition affecting the heart could together treat an aggressive form of lung cancer called non-small cell lung cancer (NSCLC), according to a study published in Cell today.

27 Apr 2012

FDA ODAC to review Onyx’s NDA for carfilzomib

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the company's new drug application (NDA) for carfilzomib for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies. ODAC will review carfilzomib at its meeting on June 20, 2012.

27 Apr 2012

Aspirin can reduce chance of dying from bowel cancer by 30%

Taking aspirin after being diagnosed with bowel cancer can reduce the chance of dying from the disease by 30 per cent, new research shows today.

27 Apr 2012

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery.

27 Apr 2012

FDA issues Complete Response Letter to Amgen’s sBLA for XGEVA

Amgen today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.

27 Apr 2012

Gamma and delta-tocopherols do prevent many cancers

Next time you need to choose between vegetable oil and margarine in that favorite recipe, think about your health and reach for the oil. While the question of whether vitamin E prevents or promotes cancer has been widely debated in scientific journals and in the news media, scientists at the Center for Cancer Prevention Research, at Rutgers Mario School of Pharmacy, and the Cancer Institute of New Jersey, believe that two forms of vitamin E - gamma and delta-tocopherols - found in soybean, canola and corn oils as well as nuts do prevent colon, lung, breast and prostate cancers.

27 Apr 2012

GSK receives FDA approval for Votrient to treat advanced soft tissue sarcoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.

27 Apr 2012

Novartis receives FDA approval for Afinitor to treat renal angiomyolipomas caused by TSC

The U.S. Food and Drug Administration approved Afinitor (everolimus), the first drug approved specifically to treat non-cancerous kidney tumors (renal angiomyolipomas) not requiring immediate surgery in patients with tuberous sclerosis complex.

27 Apr 2012

Allied Healthcare increases stake in Coridon to over 44%

Allied Healthcare Group (ASX: AHZ) announced today that post the recent capital raising it has invested a further $1 million into Coridon, increasing its holding in the company to 44.4%. Allied has increased its investment in Coridon as the Company progresses towards its Phase I study for a herpes vaccine and makes further progress on its HPV therapeutic vaccine program.

26 Apr 2012

Contraceptive pill could soon be given out to 13 year olds without prescription

According to an NHS report girls as young as 13 should be given the contraceptive pill without having to see a doctor. Normally girls and women can only go on the Pill once they have undergone a thorough consultation with a GP or nurse as it can cause side effects including blood clots.

26 Apr 2012

Experimental drug for autism works effectively in laboratory mice: Study

A new experimental drug has shown promise in autism symptoms in mice. Researchers from the National Institutes of Mental Health and Pfizer reported Wednesday that an experimental compound, called GRN-529, increased social interactions and lessened repetitive self-grooming behavior in a strain of mice bred to display autism-like behaviors.

26 Apr 2012

Australian Government must take the lead in tackling antibiotic resistance: NPS Board Chair Dr Janette Randall address to the National Press Club

NPS Board Chair Dr Janette Randall today called on the government to take the lead on a cross sectoral approach towards tackling the antibiotic-resistance crisis facing the Australian community.

26 Apr 2012

Study identifies prime target for better anti-dandruff medicines

Research on the fungus that ranks as one cause of dandruff - the embarrassing nuisance that, by some accounts, afflicts half of humanity - is pointing scientists toward a much-needed new treatment for the condition's flaking and itching.

26 Apr 2012

InDex Pharmaceuticals granted U.S. patent for novel treatment of steroid-resistant inflammation

InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.

26 Apr 2012

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.

26 Apr 2012

Vitamin D supplementation in winter can help lower blood pressure in hypertensive patients

A new study, presented at the European Society of Hypertension meeting in London, shows that vitamin D supplementation in winter can help lower blood pressure in patients with hypertension.

25 Apr 2012

Self-degradation response to antidepressant Zoloft observed in yeast cells

Princeton University researchers have observed a self-degradation response to the antidepressant Zoloft in yeast cells that could help provide new answers to lingering questions among scientists about how antidepressants work, as well as support the idea that depression is not solely linked to the neurotransmitter serotonin.

25 Apr 2012

Providers can and should work toward 'sustainable anesthesia'

Anesthesia providers can and should begin taking steps toward practicing "sustainable anesthesia," according to the May special issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

25 Apr 2012